Changes in Hong Kong stocks | Keji Pharmaceutical-B (02171.HK) rose by more than 11% CT053 commercialized and implemented CT041 research results to be unveiled in 2024 ASCO
Keji Pharmaceutical-B (02171.HK) rose by more than 11% during the day. As of press release, it rose 5.54% to HK$5.33, with a turnover of HK$9.66,200.
Keji Pharmaceutical-B (02171.HK): CT053 commercialization implementation looks forward to overseas breakthroughs
CT053, the main investment point, has been successfully commercialized, and the CT041 phase II is being promoted domestically, and we are looking forward to the NDA. We are optimistic that the company is a leading global solid tumor CAR-T company, and its CT053, CT041 and other pipelines are successive
Changes in Hong Kong stocks | Innovative drug concept stocks rose higher, Keji Pharmaceutical-B (02171) rose more than 11%, and innovative drugs ushered in a full-process support mechanism
Innovative drug concept stocks continued to rise. As of press release, Keji Pharmaceutical-B (02171) rose 10.3% to HK$5.57; Laikai Pharmaceutical-B (02105) rose 9.15% to HK$6.44; and Rongchang Biotech (09995) rose 6.29% to HK$31.25.
科濟藥業-B:二零二三年年度報告
The CAR-T market is approaching 100 billion dollars: domestic companies ensure “survival”, and multinational companies earn dollars
On March 1 of this year, Keji Pharmaceutical-B (02171)'s CAR-T therapy Zewokie Orense injection (SAKIZE) was officially approved for sale, and the number of CAR-T treatments marketed worldwide has also reached 11. Although some of these products compete with each other in terms of treatment of indications, the rapid growth in sales of leading products is still driving the rapid expansion of the global market. The Zhitong Finance App learned that the global CAR-T cell therapy market is expected to reach US$88.52 billion in 2032. The 100 billion dollar market is in sight, and it continues to boost the market's investment confidence. However, not every product
Changes in Hong Kong stocks | Keji Pharmaceutical-B (02171.HK) fell sharply by more than 16%. The company lost 748 million yuan in 23 and narrowed 16.19% year-on-year
Keji Pharmaceutical-B (02171.HK) fell sharply by more than 16%. At press time, it fell 16.78% to HK$4.77, with a turnover of HK$4.3 million.
Carsgen Therapeutics To Give Cancer Drug Oral Presentation at ASCO 2024
Carsgen Therapeutics Holdings (HKG:2171) said it will give an oral presentation of satricabtagene autoleucel on June 3 at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024, accordin
Featured announcements | Shandong Gold's Q1 net profit is expected to increase by 48.11% to 70.9% year-on-year
Xinji Shaxi: 14.16% of the company's shares held by the controlling shareholder were forcibly sold, and trading resumed today; express sales: net profit of 195.9 billion yen in the first half of the year, up 27.7% year on year; Smore International: profit after tax for the first quarter was about 339.5 million yuan, up 12.8% year on year.
Keji Pharmaceutical-B (02171.HK): CT041 abstracts were accepted for oral presentation at the 2024 American Society of Clinical Oncology Annual Meeting
Keji Pharmaceutical-B (02171.HK) issued an announcement. The company's board of directors announced that the abstract of CT041 (a candidate product targeting Claudin18.2 autologous CAR-T cells) has been received for an oral report at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Keji Pharmaceutical-B (02171.HK) made an oral report on the CT041 test data update at the 2024 ASCO Annual Meeting
Gelonghui, April 11 | Keji Pharmaceutical-B (02171.HK) announced that the abstract of CT041 (a candidate product targeting Claudin18.2 autologous CAR-T cells) has been received as an oral report at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. CT041 is a potentially world-first autologous CAR-T cell candidate targeting Claudin18.2 protein. It is used to treat Claudin18.2 positive solid tumors, mainly gastric cancer/esophagastric junction adenocarcinoma and pancreatic cancer. Ongoing trials are included
Keji Pharmaceutical (2171.HK): Seckaize has been approved for marketing and commercial release can be expected
Guide to this report: Sikaize was approved for listing. Huadong Pharmaceutical helped commercialize it. CT041 treatment for gastric cancer of at least 3L is expected to submit an NDA by the end of this year. It is optimistic about the company's long-term development and maintains an “increase” rating. Summary: Maintaining “Accumulation”
Intraday quick overview | The three major indices rose sharply, the Keji Index rose more than 2%, Bilibili rose nearly 8%, and JD and Meituan rose more than 5%
Biotech stocks rose, with Yao Ming Biotech up more than 6%, Genting Xinyao by more than 5%, Kingsray Biotech by more than 4%, and BeiGene Shenzhou by nearly 2%; Apple concept stocks generally rose, Ruisheng Technology and Gaowei Electronics by about 5%, and Shunyu Optics and Qiutai Technology by about 2%.
CARsgen Announced 2023 Annual Results
SHANGHAI, March 27, 2024 /PRNewswire/ -- March 27, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematol
Keji Pharmaceutical Announces 2023 Annual Results
SHANGHAI, March 27, 2024 /PRNewswire/ -- Keji Pharmaceutical (stock code: 2171.HK), an innovative CAR-T cell therapy company focused on treating hematologic malignancies and solid tumors, announced its 2023 results. Performance highlights at a glance, Saikaize (Zewokie Orense injection, CT053) new drug marketing application approved by the State Drug Administration CT041 received IND approval from the State Drug Administration for adjuvant treatment of pancreatic cancer with positive Claudin18.2 expression CT011 obtained from the State Drug Administration
Can the first commercial CAR-T product, which lost money in three years after launch, become a “lifesaver” for Keji Pharmaceutical? |Annual Report Interpretation
① Keji Pharmaceutical has been in a state of loss since its launch. Compared with 2022, the loss margin was relatively narrow in 2023. ② At the end of last year, the company's stock price was hit hard twice in a short period of time. ③ In March of this year, the company's first CAR-T product, Sikaize, was approved for sale. Keji Pharmaceutical expects the peak annual terminal sales of this product to reach more than 1 billion yuan.
Keji Pharmaceutical-B (02171) announced annual results. Losses attributable to shareholders of 748 million yuan narrowed 16.19% year-on-year
According to the Zhitong Finance App, Keji Pharmaceutical-B (02171) announced the results for the year ended December 31, 2023. The group achieved R&D expenditure of 662 million yuan (RMB, same below) during the period, a year-on-year decrease of 2.74%; losses attributable to shareholders amounted to 748 million yuan, a year-on-year decrease of 16.19%; and a basic loss of 1.34 yuan per share. According to the announcement, the main reason for the narrowing was the reduction in share-based remuneration, which totaled 14 million yuan for the year ended December 31, 2023, a decrease of 30 million yuan compared to 44 million yuan for the year ended December 31, 2022; R&D
CARSGEN-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
Keji Pharmaceutical (2171.HK): Sekai Sekai is listed and is looking forward to commercialization in 2024
Incident: The company released its 2023 annual report, with a net loss of 750 million yuan, a decrease of 140 million yuan compared to 890 million yuan in 2022. As of December 31, 2023, cash and cash equivalents amounted to $1.85 billion.
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
Keji Pharmaceutical-B (02171.HK) plans to hold a board meeting on March 26 to approve the annual results
Gelonghui March 12 | Keji Pharmaceutical-B (02171.HK) issued an announcement. The board of directors announced that a board meeting will be held on March 26, 2024 (Tuesday) to consider and approve the Group's annual results for the year ended 31 December 2023, and to deal with other matters.
No Data